Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Editorial: Novel Biomarkers for Type 2 Diabetes

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Editorial: The Role of Genetic and Lifestyle Factors in Metabolic Diseases

    Research output: Contribution to journalEditorialResearchpeer-review

  3. Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. In-utero Exposure to Maternal Stressful Life Events and Risk of Cryptorchidism: The Raine Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. High maternal age at first and subsequent child births in Denmark in the mid-1800s-Letter to the editor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Characterisation and localisation of the endocannabinoid system components in the adult human testis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. High-Throughput Sequencing-Based Investigation of Viruses in Human Cancers by Multienrichment Approach

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Possible link between FSH and RANKL release from adipocytes in men with impaired gonadal function including Klinefelter syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Background: Testosterone (T) is mainly excreted in the urine as testosterone glucuronide (TG). This glucuronidation is partly dependent on the UGT2B17 genotype, and TG excretion is therefore lower in men having the UGT2B17 deletion. However, the possible influence of UGT2B17 genotype on serum T during androgen therapy is unknown. We retrospectively investigated the possible association between the UGT2B17 gene polymorphism and serum T levels in hypogonadal men during Testosterone undecanoate (TU) substitution therapy. Subjects and Methods: Two hundred and seven patients treated with TU (Nebido(®)) were genotyped by quantitative polymerase chain reaction for the UGT2B17 deletion polymorphism. All were given 1000 mg TU per injection at 0, 6, and 18 weeks. Blood samples were taken 2 and 6 weeks after the first and second injection, prior to the third injection, and after 2-3 years of treatment. We analyzed for the levels of T, luteinizing hormone (LH), sex-hormone-binding globulin, estradiol, prostate specific antigen, hematocrit, hemoglobin, and total cholesterol. Results: The UGT2B17 genotype frequency was: ins/ins: 42%, ins/del: 44%, and del/del: 14%. During the initial 18 weeks of TU treatment, large intra- and inter-individual variations in serum T levels were observed. Large peaks in T levels, ranging from 6.7 to 69.5 nmol/l, were noted 2 weeks after injections, regardless of the genotype. T levels did not differ between the three genotypes prior to the third injection, but the del/del group had significantly lower levels of LH. At follow-up after 2-3 years, the injection interval or daily T dosage was not dependent on the UGT2B17 genotype. Conclusion: In conclusion, we found large intra- and inter-individual variations in serum T during standard TU treatment regimen in hypogonadal men. Only subtle differences in serum T and LH were noted according to UGT2B17 genotype, which however suggest that the UGT2B17 genotype exert modest influence on the pharmacokinetic profile of T after TU treatment.
Original languageEnglish
JournalFrontiers in Endocrinology
Volume4
Pages (from-to)94
ISSN1664-2392
DOIs
Publication statusPublished - 2013

ID: 40817282